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Abstract
Bulbar weakness and fatigue resulting in dysphagia and dysarthria is common in myasthenia gravis. In
chronic MG it is often assumed that these symptoms herald an exacerbation of the patient’s disease
and doses of cholinergic agents and immunomodulatory therapies may be increased, along with
initiation of plasma exchange. A case is presented in which dysphagia was refractory to standard
MG therapy, leading to the subsequent discovery of cricopharyngeal sphincter achalasia as the
primary cause of the patient’s symptoms rather than an assumed myasthenia gravis exacerbation. The
patient’s dysphagia resolved after esophageal dilatation. Cricopharyngeal sphincter achalasia is a
common disorder producing dysphagia in the elderly and needs to be considered in the evaluation of
a myasthenic patient with worsening dysphagia when standard myasthenia gravis therapy fails.
Discussion of myasthenia gravis, cholinergic therapy and cricopharyngeal sphincter achalasia is
undertaken. Clinicians are encouraged to consider non-neurologic causes of worsening dysphagia in
the myasthenic patient.
Introduction
Myasthenia gravis (MG) is an autoimmune neuro-
muscular junction disorder that often presents with ocular
weakness involving asymmetric ptosis and diplopia.
Oropharyngeal weakness also occurs and recurrent dysar-
thria and dysphagia not uncommonly signal exacerbations
in patients with chronic MG. Therapeutic modalities in
relapsing disease include cholinergic medication, steroids
and other immunosuppressants, along with primary
immunomodulatory agents (e.g., Intravenous Immuno-
globulin [IvIg]), and plasmapharesis. In the absence of
cholinergic crises, it is often assumed that worsening
dysphagia and dysarthria is caused by MG itself and
secondary non-neurologic causes are forgotten or over-
looked. Cricopharyngeal sphincter achalasia (CSA) is
a common disorder producing dysphagia in the elderly,
and is responsive to a number of therapeutic procedures. A
caseispresentedof apatientwithMGwithpersistentdysp-
hagia thought to be secondary to an MG exacerbation
but was found to have CSA instead which responded to
esophageal dilatation.
Case presentation
An 83-year-old Caucasian man (a national of the United
States of America) with a nine year history of myasthenia
gravis presented with complaints of difficulty swallowing.
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liquids and his pills. He felt as if there were painless
secretions in the back of his throat inhibiting swallowing.
He also had intermittent coughing and choking. He had
had similar symptoms in the past with past MG relapses.
There was no associated double vision, droopy eye lids, or
extremity weakness, and he had no complaints of short-
ness of breath. He had been stable on a combination of
Mestinon® (60 mg po q 4 hours) and Immuran® (50 mg
po bid which he had been on for the last 8-9 years) and
was intolerant to past prednisone. His last major
myasthenia gravis relapse which required intubation was
approximately 8 years ago and he responded well to
plasmapharesis at that time. On this current admission
there had been no preceding febrile illnesses and no recent
vaccinations. His past medical history was significant for
diabetes mellitus type 2, degenerative arthritis and cervical
spinal stenosis, a past left nephrectomy secondary to prior
staghorn calculi, previous lumbar spine surgery, previous
cholecystectomy, previous bariatric surgery, and past
peptic ulcers with a previous gastrointestinal bleed
secondary to past steroid use. In addition to the above,
his medication included insulin and lansoprazole.
On examination he was awake and alert with mild
dysarthria but no nasal speech patterns. There were no
dysconjugate gaze or nystagmoid patterns, nor was there
any evidence of ptosis, facial asymmetry, or fatigability.
No tongue atrophy, fasciculations, or furrowing was
noted, and the patient was able to puff both cheeks
adequately. There was no observed use of any accessory
respiratory musculature. Hismotor strength revealedgrade
5/5 on the MRC (Medical Research Council) scale in his
bilateral upper extremities proximally and distally with a
negative “pump handle” test. Lower extremity testing
revealed 5/5 strength. Neck flexors and extensors were
5-/5. Reflexes were ¼ throughout. No coordination
abnormalities were identified.
Laboratory investigations revealed a white blood cell
count of 7.77 10 × 3/cumm (normal range 4.0-10.8 10 ×
3/cumm) without a left shift. C - reactive protein was
0.33 mg/dL (normal range 0.00-0.80 mg/dL). Sodium
level was 138 mEq/L (normal range 132-152 mEq/L),
potassium was 4.6 mEq/L (normal range 3.4-5.4 mEq/L),
blood urea nitrogen was 21 mg/dL (normal range
5-25 mg/dL), creatinine was 1.0 mg/dL (normal range
0.6-1.8 mg/dL), and blood glucose was 309 mg/dL
(normal range 70-120 mg/dL). A creatinine kinase level
was normal (83 mg/dL). Acetylcholine receptor antibody
assay was elevated at 7.94 nM/L (normal less than .03 nM
per liter) and smooth muscle antibodies were negative.
Vital capacities were all normal (2.65/2.61/2.61 L) along
with maximal inspiratory pressure trials (-40/-50/-50 cm
H20). A computerized tomography scan of the neck was
performed which did not reveal any abnormal mass in the
hypopharynx or larynx.
It was thought that the patient was suffering from an MG
exacerbation presenting as a predominant dysphagia, and
his dose of Mestinon® was subsequently increased along
with initiation of IvIg. It was not felt there was any
cholinergic crises component secondary to lack of other
symptoms commonly seen in this condition. He did not
tolerate the IvIg secondary to hypertension so this was
stopped. He was subsequently given plasmapharesis but
his dysphagia continued.
Unfortunately esophageal manometry was not performed.
It was decided however to obtain a barium swallow X-ray
which showed a prominent cricopharyngeus sphincter
with incomplete relaxation and no evidence any crico-
pharyngeal bar. The patient was then scheduled for direct
laryngoscopy followed by esophagoscopy with mechan-
ical dilation of the cricopharyngeus sphincter under
general anesthesia. He tolerated the procedure well and
there were no complications.
The patients’ swallowing markedly improved and he was
discharged home on his same pre-admission medications
without any change in dose. He remains stable on his
current medication regimen without any required dose
adjustments, and is followed as an outpatient.
Discussion
Myasthenia gravis (MG) is a rare, autoimmune antibody-
mediated T cell-dependent neuromuscular junction dis-
order that often presents with fluctuating and fatigable
painless weakness involving specific muscle groups. It has
a prevalence rate of approximately 1/5000. The onset of
MG is influenced by gender and age in a bimodal fashion.
In patients younger than 40, women predominate and in
the fifth decade new cases of MG are evenly distributed
between men and women. After age 50, new cases of MG
are slightly more common in men. The course is variable,
and most patients with initial ocular weakness develop
bulbar or limb weakness within three years of initial
symptom onset. Ocular weakness involving asymmetric
ptosis and binocular diplopia is the most typical initial
presentation [1]. Early or isolated oropharyngeal weak-
ness is less common, however approximately 20% of
patients with MG will present with dysarthria and
dysphagia [2]. Recurrent dysarthria and dysphagia not
uncommonly signal exacerbations in patients with
chronic MG. Therapeutic modalities in relapsing disease
include steroids and other immunosuppressants, along
with primary immunomodulatory agents (e.g., Intra-
venous Immunoglobulin [IvIg]), plasmapharesis, and
cholinergic agents.
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doses of cholinergic agents are often increased. Choliner-
gic crisis may develop with excessive dosing of acetylcho-
linesterase inhibitors in patients with more severe MG. In
cholinergic crises increased muscarinic activity generates
copious oropharyngeal and bronchial secretions that may
obstruct the airway or be aspirated and may simulate
dysphagia. Signs of cholinergic crisis include weakness
indistinguishable from myasthenic weakness, muscle
fasciculations, and symptoms of increased muscarinic
activity including bradycardia [1]. In the absence of
cholinergic crises, it is often assumed that worsening
dysphagia and dysarthria is caused by MG itself and
secondary non-neurologic causes are forgotten or
overlooked.
The anatomical regulatory mechanisms of dysphagia in
neurologic disease are complex (Please see Schaller and
colleagues in Reference 3 for an excellent review).
Swallowing and gastrointestinal motility depend on
coordinated interactions between central and peripheral
structures regulating both voluntary and involuntary
neuromuscular activity. With regards to central causes
(e.g., stroke) exact cortical and brainstem localization is
debatable given a dearth of any detailed studies, however
a variety of new imaging studies are promising [3].
Cricopharyngeal sphincter achalasia is a common disorder
producing dysphagia in the elderly with a variable clinical
presentation. Although the exact incidence of cricophar-
yngeal dysfunction is unknown, the literature reports
cricopharyngeal achalasia as the primary cause of or as a
contributor to dysphagia in 5-25% of patients being
evaluated for clinical symptoms of dysphagia [4]. Crico-
pharyngeal achalasia may be primary or secondary.
Primary cricopharyngeal achalasia implies that the
abnormality that leads to the persistent spasm or failure
of relaxation of the cricopharyngeus muscle is confined to
the muscle, with no underlying neurologic or systemic
cause. This primary group can be further subdivided into
primary cricopharyngeal achalasia with no underlying
cause (i.e., idiopathic) or cricopharyngeal achalasia caused
by intrinsic disorders of the cricopharyngeus muscle (e.g.,
polymyositis, muscular dystrophy, hypothyroidism, or
inclusion body myositis [4].
Unfortunately medical therapy for cricopharyngeal dys-
function has been largely refractory to medical manage-
ment, including therapy with muscle relaxants. Botulinum
toxin injection into the cricopharyngeus muscle has
recently been explored as a possible therapeutic interven-
tion, but experience is limited [4]. Given this patients’
history of neuromuscular disease, these were not con-
sidered viable options.
Several surgical approaches may be considered for treat-
ment of cricopharyngeal dysfunction. Although trans-oral
andendoscopic approaches have also beenadvocated with
limited experience, the classic approach is the external
cricopharyngeal myotomy [4].
The presented patient elected to undergo the less invasive
esophageal dilation procedure as previously described.
Given the overall rarity of MG, it is unknown whether
cricopharyngeal myotomy is superior to esophageal
dilation in these patients.
In retrospect, this patient’s course including dysphagia
characteristics, lack of diurnal fatigability and fluctuation
and paucity of other MG-associated symptoms made CSA
more likely. The history of previous MG however confused
the picture, and this case serves as an important lesson. In
myasthenic patients with worsening dysphagia, all clin-
icians need to consider non-neuromuscular causes.
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